Serina Therapeutics Files 8-K on Financials

Ticker: SER · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1708599

Serina Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySerina Therapeutics, Inc. (SER)
Form Type8-K
Filed DateJan 6, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-K

TL;DR

Serina Therapeutics dropped an 8-K on Jan 6th covering financials. Check it for the latest.

AI Summary

Serina Therapeutics, Inc. filed an 8-K on January 6, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements. The company, formerly known as AgeX Therapeutics, Inc., is incorporated in Delaware and headquartered in Huntsville, Alabama.

Why It Matters

This filing provides crucial updates on Serina Therapeutics' financial health and operational status, which is important for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any unusual or high-risk events.

Key Players & Entities

  • Serina Therapeutics, Inc. (company) — Registrant
  • January 6, 2025 (date) — Date of Report
  • AgeX Therapeutics, Inc. (company) — Former Company Name
  • Huntsville, Alabama (location) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Serina Therapeutics, Inc.'s Results of Operations and Financial Condition, as well as provide Regulation FD Disclosures and Financial Statements and Exhibits.

When was this 8-K filed?

This 8-K was filed on January 6, 2025.

What was Serina Therapeutics, Inc. formerly known as?

Serina Therapeutics, Inc. was formerly known as AgeX Therapeutics, Inc.

Where are Serina Therapeutics, Inc.'s principal executive offices located?

Serina Therapeutics, Inc.'s principal executive offices are located at 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.

What is the company's state of incorporation?

The company's state of incorporation is Delaware.

Filing Stats: 641 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2025-01-06 16:07:59

Key Financial Figures

  • $0.0001 — ich registered Common Stock, par value $0.0001 per share SE R NYSE American Indicate

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. Attached hereto as Exhibit 99.1 is an investor presentation dated January 6, 2025, for Serina Therapeutics, Inc. (the "Company"). The presentation includes, among other things, preliminary, unaudited financial information as of December 31, 2024. The preliminary financial information contained in the investor presentation is unaudited and preliminary and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2024 or its results of operations as of such date. This preliminary financial information is subject to completion of the Company's normal financial close procedures. These procedures and the audit of the Company's financial statements for the year ended December 31, 2024 are ongoing and could result in changes to the preliminary financial information. The information in this Item 2.02 and in Item 7.01 is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in this report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this report is not intended to, and does not, constitute a determination or admission by the Company that, the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company or any of its affiliates.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. The information contained in Item 2.02 is hereby incorporated into this Item 7.01 by reference.

01 - Financial Statements and Exhibits

Item 9.01 - Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Investor Presentation dated January 6, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: January 6, 2025 By: /s/ Steve Ledger Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.